One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine

South African Medical Journal

Volumn 101, Issue 12, 2011, Pages 879-883

  Madhi, Shabir Ahmed ^a   Cutland, Clare ^a   Jones, Stephanie ^a   Groome, Michelle ^a   Ortiz, Esteban ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Sanof Pasteur   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; PENTAXIM; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN EXPERIMENT; HYPOTONIC HYPORESPONSIVE EPISODE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFANT; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; IRRITABILITY; LUNG TUBERCULOSIS; MASS IMMUNIZATION; NORMAL HUMAN; PATHOLOGICAL CRYING; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; SEIZURE; SEROCONVERSION; SIDE EFFECT; SOUTH AFRICA; SYSTEMIC DISEASE; TREATMENT DURATION; VOMITING;

ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED;

EID: 82555164517     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. World Health Organization. WHO Vaccine Preventable Diseases Monitoring System: Country Profle Selection Center. http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofleselect.cfm (accessed 17 August 2011).
2. Pichichero ME. New combination vaccines. Pediatr Clin North Am 2000;47(2):407-426.
3. Edwards K, Decker M. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Oft PA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier, 2008:467-517.
4. World Health Organization. Pertussis position paper. Weekly Epidemiol Rec 2010;85(40):385-400.
5. United Nations pre-qualifed vaccines: WHO list of vaccines for purchase by UN agencies. http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html (accessed 17 August 2011).
6. Plotkin S, Liese J, Madhi SA, Ortiz E. A DTaPIPV//PRP~T vaccine (Pentaxim™): a review of 16 years' clinical experience. Expert Rev Vaccines 2011;10(7):981-1005.
7. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden. Appendix 2 to eleven-year report: person-time of follow-up and incidence calculations for Sanof Pasteur vaccine specific cohorts. http://www.smittskyddsinstitutet.se/upload/Publikationer/11-y-report-app202-GSK.pdf (accessed 17 August 2011).
8. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007;12(1):34-38.
9. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007;26(9):806-810.
10. Madhi SA, Cutland C, Jones S, Groome, M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. S Afr Med J 2011;101:126-131.
11. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055-1065.
12. Newcombe RG. Interval estimation for the diference between independent proportions: comparison of eleven methods. Stat Med 1998;17(8):873-890.
13. Newcombe RG. Two-sided confdence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17(8):857-872.
14. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus infuenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999;354(9195):2063-2068.
15. Kalies H, Verstraeten T, Grote V, et al. Four and one-half-year follow-up of the efectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus infuenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. infuenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004;23(10):944-950.
16. Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 2010;118(11):878-887.
17. Von Gottberg A, de Gouveia L, Madhi SA, et al. Impact of conjugate Haemophilus infuenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 2006;84(10):811-818.
18. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus infuenzae type b (Hib) disease from Te Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005;366(9480):144-150.
19. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996;3(1):93-97.
20. Barret AS, Ryan A, Breslin A, et al. Pertussis outbreak in northwest Ireland, January - June 2010. Euro Surveill 2010;15(35):1-5.
21. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010;85(23):213-228.
22. Rennels MB. Need for polio boosters after age two years. Vaccine 2009;27(2):179-180.